Coronavirus briefing: The EMA said blood clots should be listed as a rare side effect of the Astra Zeneca jabThe epidemic
- In the EU, the infection curve is moving downwards, but Ester effects may still affect the figures.
- In the UK, cases, hospitalizations, and deaths have all continued to fall. So far, at least 47% of the population has had at least one shot.
- In the US, cases have moved sideways, while deaths point down. However, some of this might be due to under-reporting over Easter.
- In Brazil, the trend in cases and deaths points down, but the country also reported a national daily Covid deaths record on Tuesday.
- Daily cases have continued to rise in Sweden, while the trend has moves slightly downwards in other Nordic countries.
- Both the number of people in hospitals and intensive care continue to point up in Sweden.
- In the Baltics, cases in Estonia continue to fall rapidly. Cases in Lithuania point slightly up, while there is a small decline in cases in Latvia.
Policy and vaccines
- In India, a night curfew was imposed in New Delhi.
- Swedish government wants to extend the Temporary Pandemic Act, which can restrict corporate activities and public events, by four months until January.
- In Finland, according to the government's draft plan, the goal is to end the exceptional conditions in April and open restaurants to a limited extent. After this, restrictions would be removed gradually.
- The EMA will begin an investigation next week on whether clinical trials of Russia’s Sputnik V Covid-19 vaccine followed global clinical and scientific guidelines.
- The EMA said it has established a link between rare blood clots in the brain and the AstraZeneca jab. However, the EMA has not changed its guidance for the jab, saying its benefits outweigh the risks.
- ECB stepped up its purchases in March with roughly 15 bln euros more purchases than in February. Total net purchases were 96 bln euros in March, read more here.
- In Sweden, spending increased sharply during the Easter week, read more here.
Swedbank AB (publ)
Phone: +358 400 98 21 59